Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Increases By 21.7%
by Scott Moore · The Cerbat GemenGene Holdings Inc. (NASDAQ:ENGNW – Get Free Report) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totaling 1,537 shares, a growth of 21.7% from the December 31st total of 1,263 shares. Based on an average daily volume of 15,963 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 15,963 shares, the days-to-cover ratio is currently 0.1 days.
enGene Trading Down 5.7%
Shares of enGene stock traded down $0.17 during trading on Wednesday, reaching $2.79. The company’s stock had a trading volume of 954 shares, compared to its average volume of 39,160. The business’s 50-day moving average price is $2.91 and its 200-day moving average price is $1.84. enGene has a 52 week low of $0.51 and a 52 week high of $4.20.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.